Evidence map›Paper›PMID 37373658›Full record

ArticleJournal of clinical medicine2023

Valentina Lando, Lucia Calciano, Cosetta Minelli, Cristina Bombieri, Marcello Ferrari, Giovanni Malerba, Antonino Margagliotti, Nicola Murgia, Morena Nicolis, Mario Olivieri and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. The Interplay betweenInternational journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Valentina LandoUnit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.ORCID 0009-0003-6794-046X
Lucia CalcianoUnit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.ORCID 0000-0001-9801-5080
Cosetta MinelliNational Heart and Lung Institute, Imperial College London, London SW3 6LR, UK.
Cristina BombieriBiology and Genetics Section, Department of Neuroscience, Biomedicine and Movement, University of Verona, 37134 Verona, Italy.ORCID 0000-0003-0295-5938
Marcello FerrariRespiratory Diseases Section, Department of Medicine, University of Verona, 37134 Verona, Italy.
Giovanni MalerbaBiology and Genetics Section, Department of Neuroscience, Biomedicine and Movement, University of Verona, 37134 Verona, Italy.ORCID 0000-0001-8705-8560
Antonino MargagliottiUnit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-4994-7460
Nicola MurgiaDepartment of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy.
Morena NicolisUnit of Hygiene and Preventive, Environmental and Occupational Medicine, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.
Mario OlivieriUnit of Occupational Medicine, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.ORCID 0000-0001-6105-0376
James PottsNational Heart and Lung Institute, Imperial College London, London SW3 6LR, UK.
Stefano TardivoUnit of Hygiene and Preventive, Environmental and Occupational Medicine, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-9161-2189
Simone AccordiniUnit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.ORCID 0000-0003-1510-6193
University of Verona · ITImperial College London · GBUniversity of Ferrara · IT

Funding

Chiesi Farmaceutici S.p.A.Fondazione Cariverona Bando 2006Italian Medicines Agency - AIFAMinistero della Salute Ricerca finalizzata 2009 - RF-2009-1471235
6 · The paper itself

Abstract

The allergic asthma phenotype is characterized by a T helper type 2 (Th2) immune response, based on Immunoglobulin E (IgE)-mediated type 1 hypersensitivity reactions. Total IgE is the sum of all IgE types produced by the human body and is used as a biomarker of inflammation in asthma. We analysed data collected in 143 asthma cases (median age 42.1 years) from the general Italian population (GEIRD survey; 2008-2010) to identify single nucleotide polymorphisms (SNPs) in candidate genes that are associated with total IgE in adult subjects with asthma. These patients reported respiratory symptoms in response to perennial allergens and provided data on 166 SNPs tagging 50 candidate genes or gene regions. Replication of the statistically significant results was performed in 842 asthma cases from other European countries (ECRHS II survey; 1998-2002). SNP rs549908 in interleukin 18 (

Indexed as

asthmabiomarkerIL18polymorphismSNPtotal IgE

Identifiers

PMID37373658
PMCPMC10299306
OpenAlexW4380361595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.